Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TFX05-01 in advanced solid tumors
NCT05434299Phase 2Recruiting
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TFX05-01 in solid tumor (advanced stage), sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd.. Started Jun 2022; status: recruiting.
02
Drugs
TFX05-01
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05434299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05434299.